U.S. markets closed

Flexion Therapeutics, Inc. (FLXN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.13-0.49 (-7.40%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close6.62
Open6.53
Bid6.00 x 2900
Ask6.16 x 1400
Day's Range6.01 - 6.64
52 Week Range4.30 - 13.66
Volume1,108,811
Avg. Volume1,082,385
Market Cap308.291M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-1.91
Earnings DateNov 02, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Flexion Therapeutics, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The presentation will be available through an on-demand webcast beginning at 7 a.m. ET on September 13, 2021, and will be accessible on the Flexion website at http://

  • GlobeNewswire

    Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference

    BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021. To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com. Abo

  • GlobeNewswire

    Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee

    AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (